New and emerging developments in extensive-stage small cell lung cancer therapeutics

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Purpose of review Extensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8-10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC. Recent findings Some of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment. Summary Systemic therapy for SCLC has changed little over the past 30 years with the most significant advances in ES-SCLC relating to radiotherapy rather than systemic therapy. The effectiveness of prophylactic cranial irradiation and thoracic radiotherapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalCurrent Opinion in Oncology
Volume28
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Therapeutics
Cranial Irradiation
Circulating Neoplastic Cells
Standard of Care
Combination Drug Therapy
Platinum
DNA Repair
Immunotherapy
DNA Damage
Thorax
Research
Pharmaceutical Preparations

Keywords

  • genomic sequencing
  • prophylactic cranial irradiation
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New and emerging developments in extensive-stage small cell lung cancer therapeutics. / Parikh, Mamta; Riess, Jonathan; Lara, Primo N.

In: Current Opinion in Oncology, Vol. 28, No. 2, 01.03.2016, p. 97-103.

Research output: Contribution to journalReview article

@article{6654b9bf0cb0488a99d3f2aea14e5ee8,
title = "New and emerging developments in extensive-stage small cell lung cancer therapeutics",
abstract = "Purpose of review Extensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8-10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC. Recent findings Some of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment. Summary Systemic therapy for SCLC has changed little over the past 30 years with the most significant advances in ES-SCLC relating to radiotherapy rather than systemic therapy. The effectiveness of prophylactic cranial irradiation and thoracic radiotherapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC.",
keywords = "genomic sequencing, prophylactic cranial irradiation, small cell lung cancer",
author = "Mamta Parikh and Jonathan Riess and Lara, {Primo N}",
year = "2016",
month = "3",
day = "1",
doi = "10.1097/CCO.0000000000000264",
language = "English (US)",
volume = "28",
pages = "97--103",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - New and emerging developments in extensive-stage small cell lung cancer therapeutics

AU - Parikh, Mamta

AU - Riess, Jonathan

AU - Lara, Primo N

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose of review Extensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8-10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC. Recent findings Some of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment. Summary Systemic therapy for SCLC has changed little over the past 30 years with the most significant advances in ES-SCLC relating to radiotherapy rather than systemic therapy. The effectiveness of prophylactic cranial irradiation and thoracic radiotherapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC.

AB - Purpose of review Extensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8-10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC. Recent findings Some of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment. Summary Systemic therapy for SCLC has changed little over the past 30 years with the most significant advances in ES-SCLC relating to radiotherapy rather than systemic therapy. The effectiveness of prophylactic cranial irradiation and thoracic radiotherapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC.

KW - genomic sequencing

KW - prophylactic cranial irradiation

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84957658225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957658225&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000264

DO - 10.1097/CCO.0000000000000264

M3 - Review article

VL - 28

SP - 97

EP - 103

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -